Dr. Sankari Nagarajan

Biography

Sankari Nagarajan is a breast cancer research scientist investigating transcriptional regulation in disease progression of breast cancers. She completed her Integrated M.Sc. in Bio-Medical Science at Bharathidasan University, India, and obtained a prestigious competitive PhD scholarship from the German Academic Exchange Service (DAAD), moving to Georg-August-University Göttingen, Germany, to work with Prof. Dr. Steven Johnsen. Her doctoral research focused on the epigenetic reader protein BRD4 in estrogen receptor-positive (ER+) breast cancers, introducing the possibility of using Bromodomain Extraterminal domain-containing protein (BET) inhibitors as a therapeutic strategy for breast cancers. After her PhD, Nagarajan served as a Research Associate at the Cancer Research UK Cambridge Institute, where her work utilized genome-wide CRISPR-based drug resistance screens to investigate the role of the SWI/SNF chromatin remodeling complex, particularly the ARID1A subunit, in endocrine treatment responses. Promoted to Senior Research Associate at the same institute before relocating to Manchester, she now leads her own lab focusing on chromatin biology and enhancer regulation. Her lab employs cutting-edge technologies to study epigenetic regulation and enhance understanding of the pathways involved in aggressive breast cancers.

Research Interests

Experience

Awards